Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
The New England journal of medicine · 2023 · 739 citations · Adedayo Onitilo
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 573 citations · Asher Chanan-Khan
Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome.
Nature communications · 2024 · 112 citations · Nasir Malik
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
JAMA oncology · 2022 · 123 citations · Phyu Aung
The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review.
European journal of medical research · 2024 · 91 citations · Lukman Lawal
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood · 2023 · 123 citations · Asher Chanan-Khan
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 119 citations · Asher Chanan-Khan
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · 19 citations · Adedayo Onitilo